Clinical trial
Immune Checkpoint Blockade for Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
NCT03816332 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Immune Checkpoint Blockade for Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- November 8, 2019
- Completion date
- September 17, 2027
- Enrollment
- 12 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
clinical stage iii cutaneous melanoma ajcc v8, clinical stage iii cutaneous merkel cell carcinoma ajcc v8, clinical stage iv cutaneous melanoma ajcc v8, clinical stage iv cutaneous merkel cell carcinoma ajcc v8, metastatic basal cell carcinoma, metastatic melanoma, metastatic merkel cell carcinoma, metastatic skin squamous cell carcinoma, pathologic stage iii cutaneous melanoma ajcc v8, pathologic stage iii cutaneous merkel cell carcinoma ajcc v8, pathologic stage iiia cutaneous melanoma ajcc v8, pathologic stage iiia cutaneous merkel cell carcinoma ajcc v8, pathologic stage iiib cutaneous melanoma ajcc v8, pathologic stage iiib cutaneous merkel cell carcinoma ajcc v8, pathologic stage iiic cutaneous melanoma ajcc v8, pathologic stage iiid cutaneous melanoma ajcc v8, pathologic stage iv cutaneous melanoma ajcc v8, pathologic stage iv cutaneous merkel cell carcinoma ajcc v8, unresectable basal cell carcinoma, unresectable melanoma, unresectable merkel cell carcinoma